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Abstract
Background: The Leiden University Medical Center (LUMC) is the Dutch national referral centre for pregnancies
complicated by haemolytic disease of the fetus and newborn (HDFN) caused by maternal alloimmunization. Yearly,
20-25 affected fetuses with severe anaemia are transfused with intra-uterine blood transfusions (IUT). Mothers of
whom their fetus has undergone IUT for HDFN are considered high responders with regard to red blood cell (RBC)
antibody formation. Most study groups report high perinatal survival, resulting in a shift in attention towards short-
and long-term outcome in surviving children.
Methods/Design: We set up a large long-term observational follow-up study (LOTUS study), in cooperation with
the Sanquin Blood Supply Foundation and the LUMC departments of Obstetrics, Neonatology and
ImmunoHematology & Bloodtransfusion.
The first part of this study addresses several putative mechanisms associated with blood group alloimmunization in
these mothers. The second part of this study determines the incidence of long-term neurodevelopment impair-
ment (NDI) and associated risk factors in children treated with IUT. All women and their life offspring who have
been treated with IUT for HDFN in the LUMC from 1987-2008 are invited to participate and after consent, blood or
saliva samples are taken. RBC and HLA antigen profile and antibodies are determined by serologic or molecular
techniques. Microchimerism populations are tested by real time polymerase chain reaction (RT PCR).
All children are tested for their neurological, cognitive and psychosocial development using standardised tests and
questionnaires. The primary outcome is neurodevelopmental impairment (NDI), a composite outcome defined as
any of the following: cerebral palsy, cognitive or psychomotor development < 2 standard deviation, bilateral blind-
ness and/or bilateral deafness.
Discussion: The LOTUS study includes the largest cohort of IUT patients ever studied and is the first to investigate
post-IUT long-term effects in both mother and child. The results may lead to a change in transfusion policy, in
particular future avoidance of certain incompatibilities. Additionally the LOTUS study will provide clinicians and
parents better insights in the long-term neurodevelopmental outcome in children with HDFN treated with IUTs,
and may improve the quality of antenatal counselling and long-term guidance.
Background
Alloimmunization is a major transfusion problem and
deliberate transfusions may induce multiple red cell, pla-
telet and HLA specific antibodies. Some transfusion
recipients seem more susceptible for alloimmunization,
but with respect to red cell (RBC) antibodies the
mechanisms have hardly been investigated. If a pregnant
woman has RBC alloantibodies of the IgG class, which
can cross the placenta, this may lead to haemolytic dis-
ease of the fetus and newborn (HDFN). The mainstay
for the treatment of fetal anaemia is intrauterine blood
transfusion (IUT), which is associated with a risk of
immunisation to additional antigens, despite the usually
small volume of the feto-maternal haemorrhage (FMH)
of just a few millilitres. In a cohort of more than 300
women, 25% formed additional antibodies after IUT
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multiple RBC antibodies [1,2]. There is some indication
that pregnancy-induced anti-D may persist longer than
transfusion-induced D-antibodies [3]. IUT is associated
with increased FMH, containing viable HLA-haplo-
identical fetal blood cells. It is not known whether
post-pregnancy persistence of fetal cells contributes to
maintenance of antibody production.
Nowadays most study groups, including ours, report
perinatal survival rates in RBC alloimmunization treated
with IUT for alloimmune fetal anaemia of above 90%
[4-7]. This improved perinatal survival causes a shift in
attention towards the short- and long-term outcome in
surviving children. To date only a few studies with small
patient numbers (range 16 to 69) have reported on the
long-term neurodevelopmental outcome [8-14]. Little is
known on the association between hydrops fetalis and
the severity of fetal anaemia and long-term neurodeve-
lopmental outcome [6].
We started a long-term follow up study of a large
cohort to determine 1. Factors involved in the formation
of blood group antibodies and the long-term maternal
immunological effects after IUT and 2. The incidence of
long-term neurodevelopmental impairment (NDI) and
associated perinatal risk factors. This study, named the
LOTUS study (LOng Term follow-up after intra Uterine
transfusionS), is conducted by a consortium of several
disciplines involved in fetal transfusions: the Sanquin
Blood Supply Foundation and the LUMC: the depart-
ments of Obstetrics, Neonatology and ImmunoHematol-
ogy & Bloodtransfusion.
Aims
This study is conducted with two separate aims.
Part 1: “Long-term maternal immunological outcome”
The first aim is to investigate factors influencing RBC
antibody incidence and persistence.
The objectives are:
1. to measure the incidence of RBC antibodies prior
to and against RBC and HLA antigens after IUT
treatment
2. to investigate whether antibodies present after
delivery persisted and whether the fetus or the IUT
donor (or both) had provided the offending antigen
3. to investigate whether formation of particular RBC
a n t i b o d i e si sa s s o c i a t e dw i th maternal Major Histo-
compatibility Complex (MHC) class II alleles
4. to evaluate whether fetal and/or donor (despite
irradiation of RBC) chimerism is associated with per-
sistence of RBC antibodies
5. to study the long-term maternal health effects by
a protocolled questionnaire aiming to identify possi-
ble maternal immune deviations (e.g. autoimmune
diseases) and a screening for the presence of autoim-
mune antibodies
Part 2: “Long-term paediatric neurodevelopmental
outcome”
The second aim is to study the long term health and
neurodevelopment in children post IUT treatment. The
objectives are:
6. to determine the incidence of NDI
7. to investigate the risk factors for developing long-
term NDI. Potential risks may include: prematurity,
severity of fetal anaemia, presence and severity of
fetal hydrops, number of IUT procedures, severe
neonatal morbidity (including respiratory distress
syndrome, intraventricular haemorrhage ≥ grade 3
[15], periventricular leukomalacia ≥ grade 2 [16],
necrotising enterocolitis ≥ grade 2 [17] and/or sep-
sis) and perinatal asphyxia.
Methods
Study population
The Leiden University Medical Center (LUMC) is the
single national referral centre in the Netherlands for the
management of pregnancies complicated by severe fetal
anaemia. All women and their live-born children, trea-
ted with IUT for severe fetal alloimmune anaemia from
1987-2008 (20 years) in the LUMC are asked to partici-
pate in the study. Women with no live-born children
will be excluded. In the period 1987-2008 340 women
gave birth to 395 living children.
The LOTUS study started on September 1
st 2008. To
date (January 2010) we included 225 families with 258
children. Seven families refused to participate, 3 families
only filled out the questionnaires and 9 families had
moved abroad. The lost-to-follow-up rate is currently
16%. We expect an inclusion rate above 80% and to
finalise the inclusion period by the end of 2010.
Procedure
Mothers and children are invited to visit one of our out-
patient clinics. After informed consent, in case of chil-
dren less than 16 years of age provided by parents or
care-taker, blood samples are withdrawn from both
mothers and children. From young children, instead of a
blood sample, a mouth-swap or a saliva sample can be
taken. From all women, RBC blood group antigens are
known (Rhesus, Kell, Duffy, Kidd and MS), as well as
the RBC antibody specificities prior to IUT and after
delivery. RBC antigen profile for clinically relevant anti-
gens of fetal and (IUT) donor RBC is completed as
much as possible from the databases of Sanquin and the
LUMC. Missing RBC and HLA antigens and antibodies
will be typed. Physical and neurological examination is
performed in all children between 2 to 22 years of age.
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ment is performed in all children between 2 to 17 years
of age.
Data collection
The following maternal and fetal baseline characteristics
are collected from the LUMC Rhesus-database:
- Maternal and fetal baseline characteristics
a. Type of red cell alloimmunization
b. Course and level of Antibody-Dependent Cell-
mediated Cytotoxic assay (ADCC) during preg-
nancy (if applicable)
c. Number of IUT
d. Route of IUT transfusion & estimated FMH
e. Perinatal maternal transfusions
f. Fetal haemoglobin (Hb) concentration before
IUT
g. Presence of severe fetal anaemia (>5 SD from
reference [Hb] for gestational age)
h. Presence of fetal hydrops, classified as mild or
severe
The following neonatal baseline characteristics are
extracted from the medical charts:
a. Birth weight, gestational age, gender
b. Haemoglobin concentration at birth
c. Use of exchange transfusions
d. Use of top up red cell transfusion until 3
months of life
e. Neonatal morbidity: kern-icterus, sepsis,
respiratory distress syndrome, necrotising entero-
colitis [17], retinopathy of prematurity [18],
intraventricular haemorrhage [15], periventricular
leukomalacia [16], postpartum hydrops fetalis
requiring drainage of ascites or pleural effusion,
cholestasis, sepsis (defined as a proven infection,
a positive blood culture, and clinical signs of
infection)
f. Perinatal asphyxia (defined as three of more of
the following five criteria: non-reassuring CTG
patterns, umbilical cord arterial pH less than
7.10, Apgar score less than 5 at 5 minutes, failure
of spontaneous breathing at 5 minutes, onset of
multiple organ failure)
Study outcome
Part 1: “Long-term maternal immunological outcome”
The primary outcome is an association between MHC
class II alleles and particular RBC antibodies. Most RBC
polymorphisms are based on single nucleotide differ-
ences. Red cell alloimmunization needs the indirect
pathway of antigen stimulation. IgG antibodies can only
be formed if T-cell help is signalled to the appropriate B
cells. Differential immunogenicity of mismatched anti-
gens is dependent on MHC-restricted potential of anti-
gen presentation, leading to activation of T cells. The
frequencies of specific HLA class II antigens will be
compared in women with and without specific RBC
antibodies with a chi-square or Fisher exact test.
Antibodies All women are tested for the persistence of
the various RBC antibodies present after the last IUT
and new developed additional antibodies by standard
serologic techniques. HLA antibodies are screened by
ELISA and specificity is determined by luminometer-
based technology. The data on RBC and HLA antigens
of children and donors will be completed. RBC antigen
profiles of children and donors will be compared with
antibody specificities that disappeared or persisted to
determine whether the IUT donor and/or the fetus pro-
vided the offending antigens. Using MCH typing, we
aim to assess MHC restriction of (specific) RBC
antibodies.
Microchimerism will be determined in whole blood
and, where applicable, within leukocyte subpopulations
by Rhesus D and Y chromosome specific RT-PCR.
The presence of fetal chimerism and the nature of the
chimeric cells in women with persistent (RBC/HLA)
antibodies will be compared to women in whom antibo-
dies are no longer detectable.
Maternal health assessment Mothers are asked to fill
out a questionnaire with the emphasis on development
of autoimmune disease. Maternal blood samples are
screened for a selection of auto-antibodies e.g. relevant
for scleroderma.
Part 2: “Long-term paediatric neurodevelopmental
outcome”
The primary outcome is the composite outcome termed
NDI, which is defined as the presence of at least one of
the following: abnormal neurological outcome (cerebral
palsy), cognitive or psychomotor development score < 2
SD, bilateral blindness, and bilateral deafness requiring
amplification. The following potential predictors for
N D Iw i l lb es t u d i e di nau n i v a r i a t el o g i s t i cr e g r e s s i o n
model: praematurity, severity of fetal anaemia, presence
and severity of fetal hydrops, number of IUT proce-
dures, severe neonatal morbidity (including respiratory
distress syndrome, intraventricular haemorrhage ≥ grade
3 [17], periventricular leukomalacia ≥ grade 2 [18],
necrotising enterocolitis ≥ grade 2 [15] and/or sepsis)
and perinatal asphyxia. Multivariable logistic regression
model will be used to measure the independent effects
of potential predicting factors on outcome.
Neurological outcome In this study the neurological
outcome is assessed in all children by a single pediatri-
cian by performing a neurological examination according
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dysfunction, or abnormal. A minor neurological dysfunc-
tion is defined as a moderate abnormality of tone, posture,
and movement leading to only minor functional impair-
ment or a minor developmental delay. Abnormal develop-
ment is defined as severe abnormality of tone, posture, and
movement leading to functional impairment and/or a delay
in motor development. Presence of cerebral palsy (CP) is
assessed according to the criteria of the European CP Net-
work and classified as diplegia, hemiplegia, quadriplegia,
dyskinetic or mixed [20].
Cognitive and psychomotor development Cognitive
and psychomotor development of children aged 2 to 3
years is assessed according to the Dutch version of the
Bayley Scales of Infant Development, 2
nd edition (BSID-
II) [21]. BSID-II scores provide a mental developmental
index (MDI) and a psychomotor developmental index
(PDI). The MDI and PDI follow a normal distribution
curve with a mean score of 100 and a standard deviation
of 15. Scores are classified into one of three categories:
normal limits (standard scores of ≥ 85); mildly delayed
(standard scores of 70-84); and significantly delayed
(standard scores of ≤ 70).
Children between 3 and 7 years of age are tested with
the Dutch version of the Wechsler Preschool Perfor-
mance Scale of Intelligence, 3
rd edition (WPPSI-III-NL)
[22]. Cognitive development in children between 7 and
16 years of age is assessed with the Dutch version of the
Wechsler Intelligence Scale for Children, 3
rd edition
(WISC-III-NL) [23]. Both tests provide a full scale IQ
score, a Verbal IQ and a Performance IQ. Scores have a
mean of 100 and a SD of 15. Scores of <70 are classified
as extremely low, 70 to 79 as borderline, 80 to 89 as low
average, 90 to 110 as average, 111 to 119 as high aver-
age, 121 to 130 as superior, and ≥ 130 as very superior.
All tests are performed by a licensed psychologist.
Psychosocial functioning and Health related Quality
of life Psychosocial follow-up is assessed in children
between 4 years to 16 years of age using the Dutch ver-
sion of the Strengths and Difficulties Questionnaire
(SDQ) [24]. The SDQ is available as an informant-rated
version for children aged 4 years and older (to be com-
pleted by parents, teachers or caregivers). The SDQ
assesses mental and behavioural difficulties and
strengths along the following dimensions: emotional
symptoms, conduct problems, hyperactivity/inattention,
peer problems and prosocial behaviour. Each scale con-
sists of 5 items, each rated on a 3-point scale (not true,
somewhat true and certainly true). Higher scores indi-
cate more problems on the respective difficulties dimen-
sion or less appropriate behaviour for the prosocial
scale. In addition to dimension-specific scores, the first
4 scales can be summed up to a total difficulties score,
with higher scores indicating more problems.
Health related Quality of Life (HRQoL) is assessed in
children between 6 years and 22 years of age using the
TNO AZL Child Quality Of Life (TACQOL) [25] and the
TNO Adult Quality of Life (TAAQOL) [26]. The TAC-
QOL child- and parent form cover 7 eight-item domains
of life: physical complaints, motor functioning, autonomy,
cognitive functioning, social functioning, positive emotions
and negative emotions. The TACQOL assesses the fre-
quency of difficulties experienced in ‘the last few weeks’
with response categories: never, occasionally or often. If a
difficulty is experienced occasionally or often, the emo-
tional reaction to this problem is determined. Items are
scored by assigning a value of 4 to the ‘never’ response, a
value of 3 to a ‘feeling fine’ response, a value of 2 to a ‘feel-
ing not so good response, a value of 1 to a ‘feeling quite
bad’ response and a value of 0 to a ‘feeling bad’ response.
The scores in each domain range from 0 to 32. The scales
for positive and negative emotions, asking for the fre-
quency of moods on a 3-pointscale (score 0 ‘never’, score
1 ‘occasionally’, score 2 ‘often’), range from 0 to 16. In all
seven domains higher scores indicate better HRQoL.
The TAAQOL covers 12 domains: gross motor func-
tioning, fine motor functioning, pain, sleeping, cognitive
functioning, social functioning, daily activities, sexual
activity, vitality, happiness, depressive moods, and
aggressiveness. First the frequency of occurrence of a
specific complaint or limitation during the last month is
asked. If such a problem has occurred, the subjective
appraisal of this problem is assessed. A score of 1 is
given when there is no limitation, a score of 2 when
there is a limitation (’a little’, ‘some’ or ‘al o t ’) but when
the person is not bothered by this limitation; a score of
3 when there is a limitation and the person experiences
this limitation ‘al i t t l e ’ negatively; a score of 4 when
there is a limitation and the person experiences this lim-
itation ‘quite a lot’ negatively; and a score of 5 when
there is a limitation and the person experiences this lim-
itation ‘very much’ negatively. Scores of each subscale
are normalised to a scale ranging from 0 to 100, with
higher scores indicating better HRQoL.
Life-achievement forms based on the POPS-19 study
are obtained in children between 8 and 22 years of age.
All tests and questionnaires for the parents and children
are summarised in table 1.
Ethical approval
The LOTUS study was approved by the ethics commit-
tee of the Leiden University Medical Centre on June 1
st
2008 (P08.080).
Discussion
Part 1: “Long-term maternal immunological outcome”
Pregnant women with Rh-D alloimmunization resulting
in haemolytic disease of the fetus, receive a median of
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ment is associated with a high risk on additional mater-
nal RBC antibody production and the immunisation rate
exceeds that of any poly-transfused patient group [1,2].
The mechanism of this high immunisation rate is still
unknown and the aim of this study is to unravel several
factors that may contribute to this phenomenon.
MHC-restriction in more or less efficient presentation
of RBC antigens may play a role. According to the study
by Noizat-Pirenne et al [27,28], all patients with anti-Fy
a
had a specific HLA DRB1 phenotype, compared to 19%
in the ethnic control population. Less specific relation-
ships were found for the Jk
a [28,29] and K [27] antigen.
In uncomplicated pregnancy, approximately 15-30% of
single- or multiparous women form antibodies directed
against inherited paternal HLA antigens of the fetus
[30-32]. The current study investigates HLA alloimmu-
nization in pregnancies complicated by maternal RBC
immunisation, in order to explore whether high anti-
body responder ship and persistence of antibodies is
associated with RBC immunisation and/or fetal micro-
chimerism [33]. Several studies have described a rela-
tionship between high levels of microchimerism and the
increased risk on auto-immune diseases, e.g. systemic
sclerosis [34-36]. We will investigate whether these
mothers are at an increased risk for the development of
auto-immune diseases.
The results of this study may lead to a change in
transfusion policy, in particular future avoidance of cer-
tain mismatches.
Part 2: “Long-term paediatric neurodevelopmental
outcome”
Only a few small studies have focused on the paediatric
long-term neurodevelopmental outcome after IUT. Most
follow-up studies showed that despite the severity of
fetal haemolytic disease, developmental outcome for
children treated with IUT is usually normal [4-7,10].
Doyle et al. reported on the sensorineural outcome at 2
years of age in 38 survivors of IUTs. The majority of
these infants (92%) showed no sensorineural disability at
2 years of age [8]. Hudon et al. studied the neurodeve-
lopmental outcome in 40 infants with HDFN treated
with IUT. All infants showed normal developmental
outcome at the age of 62 months [11]. Grab et al.
described 35 infants treated with IUTs for severe ery-
throblastosis. At 6 years of age no moderate or severe
neurological impairment was observed [12]. Harper et
al. evaluated long-term outcome in 18 hydropic fetuses
treated with IUT. Death or major neurological morbidity
Table 1 An overview of child and proxy questionnaires and tests for paediatric neuromotor, cognitive and
psychosocial development in all children treated with IUT for alloimmune fetal anaemia
Age Child Questionnaire Proxy Questionnaire Life Achievement Cognitive Development
2 BSID-III-NL
3
4
5 Proxy questionnaire WPPSI-III-NL
6
7
8
9
10
11
12 TACQOL SDQ/
13 TACQOL
14
15
16 WISC-III-NL
17 Child questionnaire
18
19
20 TAAQOL
21
22
TACQOL TNO AZL Child Quality of Life, TAAQOL TNO AZL Adult Quality of Life, SDQ Strengths and Difficulties Questionnaire, BSID-II-NL Bailey Scales of Infant
Development 2
nd edition, WPPSI-III-NL Wechsler Pre-school Performance Scale of Intelligence 3
rd edition, WISC-III-NL Wechsler Intelligence Scale for Children 2
nd
edition.
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had major neurological sequelae [13]. The largest fol-
low-up study to date was performed by our group more
than a decade ago and included 69 infants with HDFN.
We found that the neurodevelopmental outcome for
children with HDFN treated with IUTs compared
favourably with a group of high-risk, very low birth
weight infants (10% versus 18%, respectively), but less
favourably with a healthy control group (10% versus 6%,
respectively) [10]. The main limitation of all studies is
the small number of patients included (from 16 to a
maximum number of 69 children). Moreover, cognitive
development and quality of life assessment were often
not reported.
Importantly, although fetal hydrops was found to be
associated with increased mortality, not much is known
about the association between the severity of fetal anae-
mia or other risk factors and long-term neurodevelop-
mental outcome [7].
This study will address long term outcome in a large
number of children (>330) and will enable us to deter-
mine the association between several, potentially clini-
cally relevant risk factors and long-term outcome. The
LOTUS study will provide clinicians and parents better
insights in the long-term outcome of children with RBC
alloimmunization treated with IUTs, and may improve
the quality of antenatal counselling on long-term neuro-
developmental outcome.
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